SCHEMBL21145360

SCHEMBL21145360

CC(C)(C)OC(=O)N1CCCC(F)(C(=O)NN)C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 2/20 0.49
HPGD P15428 1/20 0.39
HDAC2 Q92769 2/20 0.39
USP2 O75604 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EPHX1 P07099 1/20 0.37
MAPT P10636 1/20 0.37
MMP2 P08253 1/20 0.37
MMP13 P45452 1/20 0.37
MMP14 P50281 1/20 0.37
ADAM17 P78536 1/20 0.37
HDAC1 Q13547 1/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
EPHX2 P34913 1/20 0.36
MKNK1 Q9BUB5 1/20 0.36
CYP11B2 P19099 1/20 0.35
MEN1 O00255 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23210569 0.92 USP30 (0.43) USP30HDAC2USP2SMN1; SMN2EPHX1
SCHEMBL1441490 0.83 USP30 (0.46) USP30HPGDHDAC2USP2SMN1; SMN2
SCHEMBL20028676 0.83 USP30 (0.45) USP30HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL27096725 0.83 USP2 (0.45) USP30HPGDHDAC2USP2SMN1; SMN2
SCHEMBL1439256 0.83 USP30 (0.45) USP30HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL28779043 0.80 USP30 (0.46) USP30HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL20028915 0.80 USP30 (0.46) USP30HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL1262593 0.78 HPGD (0.45) USP30HPGDUSP2SMN1; SMN2EPHX1
SCHEMBL21996473 0.78 DGAT1 (0.34) USP30ALDH1A1CYP1A2CYP2D6CYP2C9
SCHEMBL23210377 0.78 DGAT1 (0.34) USP30ALDH1A1CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109790148-B Cyano-substituted heterocycles having USP30 inhibitor activity 特殊治疗有限公司 2022-06-07 CN disclosed
EP-3519397-B1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LTD (GB) 2021-05-19 EP disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 MISSION THERAPEUTICS LIMITED (GB) 2021-02-23 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 MISSION THERAPEUTICS LIMITED (GB) 2019-07-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190218215-A1 CYANO-SUBTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 USP30, USP28, USP1 USP30 1/4885HPGD 791/4885HDAC2 1566/4885
US-10927110-B2 Cyano-subtituted heterocycles with activity as inhibitors of USP30 USP30, USP28, USP1 USP30 1/4885HPGD 791/4885HDAC2 1566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.